Float Short %

8.42

Margin Of Safety %

Put/Call OI Ratio

0.11

EPS Next Q Diff

0.44

EPS Last/This Y

-3.02

EPS This/Next Y

1.49

Price

7.4

Target Price

42.05

Analyst Recom

Performance Q

-38.22

Upside

-2,699.1%

Beta

2.86

Ticker: CRBP

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-01-23	CRBP	8.72	0.06	0.01	2756
2026-01-26	CRBP	9.28	0.06	0.01	2916
2026-01-27	CRBP	9.51	0.06	0.00	3271
2026-01-28	CRBP	8.68	0.05	0.00	3379
2026-01-29	CRBP	8.63	0.05	0.01	3482
2026-01-30	CRBP	8.25	0.05	0.22	3647
2026-02-02	CRBP	8.26	0.05	1.09	3655
2026-02-03	CRBP	8.13	0.06	0.00	3711
2026-02-04	CRBP	7.98	0.06	0.81	3724
2026-02-05	CRBP	7.43	0.06	7.57	3778
2026-02-06	CRBP	7.83	0.10	2.00	3956
2026-02-09	CRBP	7.9	0.10	0.29	3961
2026-02-10	CRBP	7.9	0.10	2.00	3978
2026-02-11	CRBP	7.56	0.10	0.00	3981
2026-02-12	CRBP	7.8	0.10	0.45	3984
2026-02-13	CRBP	7.58	0.10	0.00	3992
2026-02-17	CRBP	7.51	0.10	2.29	4031
2026-02-18	CRBP	7.47	0.12	0.00	4094
2026-02-19	CRBP	7.67	0.11	0.00	4070
2026-02-20	CRBP	7.39	0.11	0.00	4072
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-01-23	CRBP	8.69	-104.5	-28.8	-6.71
2026-01-26	CRBP	9.27	-104.5	-55.0	-6.71
2026-01-27	CRBP	9.50	-104.5	-39.2	-6.71
2026-01-28	CRBP	8.68	-104.5	-12.3	-6.71
2026-01-29	CRBP	8.64	-104.5	-32.8	-6.71
2026-01-30	CRBP	8.26	-104.5	-22.0	-6.71
2026-02-02	CRBP	8.32	-104.5	-36.9	-6.71
2026-02-03	CRBP	8.13	-104.5	-29.8	-6.71
2026-02-04	CRBP	7.96	-104.5	-30.3	-6.71
2026-02-05	CRBP	7.39	-104.5	-6.9	-6.71
2026-02-06	CRBP	7.79	-104.5	-54.4	-6.71
2026-02-09	CRBP	7.93	-104.5	-41.0	-6.71
2026-02-10	CRBP	7.90	-104.5	-36.1	-6.71
2026-02-11	CRBP	7.57	-104.5	-20.2	-6.71
2026-02-12	CRBP	7.85	-104.5	-52.8	-6.71
2026-02-13	CRBP	7.59	-104.5	-23.4	-6.71
2026-02-17	CRBP	7.48	-104.5	-30.7	-6.71
2026-02-18	CRBP	7.46	-104.5	-30.8	-6.71
2026-02-19	CRBP	7.65	-104.5	-	-6.71
2026-02-20	CRBP	7.40	-104.5	-	-6.71
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-01-23	CRBP	-4.14	-1.01	8.27
2026-01-26	CRBP	-4.14	5.08	8.27
2026-01-27	CRBP	-4.14	5.08	8.27
2026-01-28	CRBP	-4.14	5.08	8.27
2026-01-29	CRBP	-4.14	5.08	8.27
2026-01-30	CRBP	-4.14	5.08	8.27
2026-02-02	CRBP	-4.14	5.29	8.27
2026-02-03	CRBP	-4.14	5.29	8.27
2026-02-04	CRBP	-4.45	5.29	8.27
2026-02-05	CRBP	-4.45	5.29	8.27
2026-02-06	CRBP	-4.45	5.29	8.27
2026-02-09	CRBP	-4.45	6.98	8.27
2026-02-10	CRBP	-4.46	6.98	8.27
2026-02-11	CRBP	-4.46	6.98	8.42
2026-02-12	CRBP	-4.46	6.98	8.42
2026-02-13	CRBP	-4.46	6.98	8.42
2026-02-17	CRBP	-4.46	10.65	8.42
2026-02-18	CRBP	-5.52	10.65	8.42
2026-02-19	CRBP	-5.52	10.65	8.42
2026-02-20	CRBP	-5.52	10.65	8.42
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-1.9

Avg. EPS Est. Current Quarter

-1.59

Avg. EPS Est. Next Quarter

-1.46

Insider Transactions

-5.52

Institutional Transactions

10.65

Beta

2.86

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

91.9

Max Drawdown 5-Year %

-97.6

Target Price

42.05

P/E

Forward P/E

PEG

P/S

P/B

1.01

P/Free Cash Flow

EPS

-5.51

Average EPS Est. Cur. Y

-6.71

EPS Next Y. (Est.)

-5.21

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.36

Return on Equity vs Sector %

-102.3

Return on Equity vs Industry %

-84.8

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.32

EBIT Estimation

Corbus Pharmaceuticals Holdings

Sector: Healthcare

Industry: Biotechnology

Employees: 28

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

stock quote shares CRBP – Corbus Pharmaceuticals Holdings, Inc. Stock Price stock today

news today CRBP – Corbus Pharmaceuticals Holdings, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch CRBP – Corbus Pharmaceuticals Holdings, Inc. yahoo finance google finance

stock history CRBP – Corbus Pharmaceuticals Holdings, Inc. invest stock market

stock prices CRBP premarket after hours

ticker CRBP fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: CRBP

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y